EUVIMEDEUVIMED entdecken
Open Access

Impact of antigen loading in tolerogenic nanoparticles to mitigate Th2-mediated allergic lung inflammation

Brianna L Scotland iD, Shruti Dharmaraj iD, Andrea L Cottingham iD, Nhu Truong iD, Svetlana P Chapoval iD, Achsah D Keegan iD, Ryan M Pearson iD

Drug Delivery and Translational Research · 2024

DOI: 10.1007/s13346-024-01632-8 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Drug Delivery and Translational Research, 2024. Verfasst von Brianna L Scotland und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutical Sciences, University of Maryland School of Pharmacy, 20 N. Pine Street, Baltimore, MD, 21201, USA. Hauptthemen laut MEDLINE: Th2 Cells, Nanoparticles, Ovalbumin, Polylactic Acid-Polyglycolic Acid Copolymer. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 55 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: National Institute of Allergy and Infectious Diseases, NIGMS NIH HHS, NCI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Allergic disease is a major global health concern that imposes significant life-altering and economic burdens on affected individuals. However, there is still no cure. Polymer-based nanoparticles (NP) have shown the potential to induce antigen (Ag)-specific immune tolerance in various Th1/17 and Th2-mediated immune disorders including autoimmunity and allergy. Common methods by which Ags are associated with NPs are through surface conjugation or encapsulation. However, these Ag delivery strategies can be associated with several caveats that dampen their effectiveness such as uncontrolled Ag loading, a high Ag burst release, and an increased immune recognition profile. We previously developed Ag-polymer conjugate NPs (acNPs) to overcome those noted limitations, while allowing for controlled delivery of precise quantities of Ag to innate immune cells for Ag-specific CD4 T cell modulation. Here, we utilized ovalbumin (OVA) protein-poly(lactic-co-glycolic acid) (PLGA) conjugate NPs (acNP-OVA) to elucidate the impact of Ag loading on the induction of Th2 tolerance using a prophylactic and therapeutic OVA/ALUM-induced mouse model of allergic lung inflammation (ALI) in comparison to Ag-encapsulated PLGA NPs (NP(Ag)). We demonstrate that acNP-OVA formulations reduced OVA-specific IgE and inhibited Th2 cytokine secretions in an Ag loading-dependent manner when administered prophylactically. Administration of acNP-OVA to pre-sensitized mice did not affect OVA-specific IgE and Th2 cytokines tended to be reduced, however, there was no clear Ag loading dependency. acNP-OVA with medium-to-low Ag loadings were well tolerated, while formulations with high Ag loadings, including NP(Ag) resulted in anaphylaxis. Overall, our results clarify the relationship between Ag loading and Ag-specific IgE and Th2 cytokine responses in a murine model of ALI, which provides insight useful for future design of tolerogenic NP-based immunotherapies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Th2 CellsNanoparticlesOvalbuminPolylactic Acid-Polyglycolic Acid CopolymerImmune ToleranceAntigensAnimalsMicePneumoniaFemaleMice, Inbred BALB CHypersensitivityCytokinesDisease Models, Animal

Stichwörter der Autor:innen

Airway inflammationAntigen-conjugated nanoparticlesImmunotherapyTh2 immune response

Substanzen

OvalbuminPolylactic Acid-Polyglycolic Acid CopolymerAntigensCytokines

Autor:innen und Institutionen

  • Department of Pharmaceutical Sciences, University of Maryland School of Pharmacy, 20 N. Pine Street, Baltimore, MD, 21201, USA.
  • Department of Microbiology and Immunology, University of Maryland School of Medicine, 685 W. Baltimore Street, Baltimore, MD, 21201, USA.
  • Center for Vascular and Inflammatory Diseases, University of Maryland School of Medicine, 800 W. Baltimore Street, Baltimore, MD, 21201, USA.
  • Marlene and Stewart Greenebaum Comprehensive Cancer Center, University of Maryland School of Medicine, 22 S. Greene Street, Baltimore, MD, 21201, USA.
  • Department of Pharmaceutical Sciences, University of Maryland School of Pharmacy, 20 N. Pine Street, Baltimore, MD, 21201, USA. rpearson@rx.umaryland.edu.
  • Department of Microbiology and Immunology, University of Maryland School of Medicine, 685 W. Baltimore Street, Baltimore, MD, 21201, USA. rpearson@rx.umaryland.edu.

ORCID-Profile: Brianna L Scotland, Shruti Dharmaraj, Andrea L Cottingham, Nhu Truong, Svetlana P Chapoval, Achsah D Keegan, Ryan M Pearson

Förderung

  • National Institute of Allergy and Infectious Diseases
  • NIGMS NIH HHS
  • NCI NIH HHS
  • NIAID NIH HHS
  • NCATS NIH HHS
  • National Institute of General Medical Sciences
  • National Cancer Institute
  • National Center for Advancing Translational Sciences

Zitieren

APA

Scotland, B. L., Dharmaraj, S., Cottingham, A. L., Truong, N., Chapoval, S. P., Keegan, A. D., & Pearson, R. M. (2024). Impact of antigen loading in tolerogenic nanoparticles to mitigate Th2-mediated allergic lung inflammation. Drug Delivery and Translational Research. https://doi.org/10.1007/s13346-024-01632-8

Vancouver

Scotland BL, Dharmaraj S, Cottingham AL, Truong N, Chapoval SP, Keegan AD, et al. Impact of antigen loading in tolerogenic nanoparticles to mitigate Th2-mediated allergic lung inflammation. Drug Delivery and Translational Research. 2024. doi:10.1007/s13346-024-01632-8

BibTeX
@article{Scotland2024,
  author = {Scotland, Brianna L and Dharmaraj, Shruti and Cottingham, Andrea L and Truong, Nhu and Chapoval, Svetlana P and Keegan, Achsah D and Pearson, Ryan M},
  title = {Impact of antigen loading in tolerogenic nanoparticles to mitigate Th2-mediated allergic lung inflammation},
  journal = {Drug Delivery and Translational Research},
  year = {2024},
  doi = {10.1007/s13346-024-01632-8}
}
Kostenlos starten →